Clinical Study

A Prospective Phase II Trial Of Novottf-100A With Bevacizumab (Avastin) In Patients With Recurrent Glioblastoma

Posted Date: Mar 28, 2018

  • Investigator: Rekha Chaudhary
  • Specialties: Hematology/Oncology, Oncology, Neurosurgery, Cancer, Neurology
  • Type of Study: Drug

The purpose of this study is to determine the efficacy of the combination of Bevacizumab and NovoTTF-100A in Bevacizumab naïve (meaning you have never received bevacizumab before) patients with recurrent GBM as measured by 6-month progression free survival.

Criteria:

To Be Eligible For This Study, Patients Must Have Been Diagnosed With A Brain Tumor Called Glioblastoma Or Other Grade Iv Malignant Glioma (I.E. Gliosarcoma, Small Cell Glioblastoma, Etc).

Keywords:

Cancer, Glioma, Brain Tumor, Cae3313, Brain

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com